This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

60/100

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Genetics

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Recent trials of anti-amyloid-β (Aβ) monoclonal antibodies, including lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have limited clinical benefits and their use comes with a significant risk of serious adverse events. Indeed, in our review, we observed a stage-dependent neuroinflammatory process in the AD brain.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., et al. (2024). Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches? Journal of neuroinflammation. https://doi.org/10.1186/s12974-024-03163-y

Vancouver

Lista S, Imbimbo BP, Grasso M, Fidilio A, Emanuele E, Minoretti P, et al. Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches? Journal of neuroinflammation. 2024. doi:10.1186/s12974-024-03163-y. PMID: 39080712.

BibTeX

@article{lista2024-39080712,
  author  = {Lista, S. and Imbimbo, B. P. and Grasso, M. and Fidilio, A. and Emanuele, E. and Minoretti, P. and López-Ortiz, S. and Martín-Hernández, J. and others},
  title   = {{Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?}},
  journal = {Journal of neuroinflammation},
  year    = {2024},
  doi     = {10.1186/s12974-024-03163-y},
  pmid    = {39080712},
  url     = {https://doi.org/10.1186/s12974-024-03163-y}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: this is a follow-up (cohort) study. People are observed over time and not assigned to anything, so an association can reflect other differences between groups. Look at how long follow-up lasted, how many dropped out, and whether the authors adjusted for age, education and other health conditions.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded moderate. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Moderate means the abstract mentions a cohort, case-control or longitudinal design. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Background Recent trials of anti-amyloid-β (Aβ) monoclonal antibodies, including lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have limited clinical benefits and their use comes with a significant risk of serious adverse events.
Indeed, in our review, we observed a stage-dependent neuroinflammatory process in the AD brain.

Why it matters

This review notes that recent trials of anti-amyloid antibodies such as lecanemab and donanemab showed limited clinical benefits and a significant risk of serious adverse events. It describes a stage-dependent neuroinflammatory process in the Alzheimer's brain and discusses tracking inflammatory biomarkers for individualized treatment approaches.

New to this subject? Start with our plain-English guide: Genetics →

Study details

Study designlongitudinal study
Evidence strengthModerate

How this study scored 60/100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of neuroinflammation)
Journal's citation record	2 / 4	Journal of Neuroinflammation: journal h-index 216 (OpenAlex, 2026-10-29)
Study design	7 / 12	A longitudinal study following the same people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	4 / 7	Cited 79 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	19.8 citations a year over 4 year(s) since 2024
Impact for its field and year	4 / 6	Cited 10.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	3 / 6	Cited by 10 other studies in this library
Still being cited	3 / 4	Cited 79 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Filippo Caraci: h-index 64 (OpenAlex, whole career)
Institution's track record	1 / 3	Sapienza University of Rome: institution h-index 1,145 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 9 institution(s) in 3 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 39080712)
Free to read	2 / 2	Free to read
Total	60 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 71.

Later studies that cite this one

10 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Genetics from nearby years

Also in Genetics

210 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.

Similar studies

More on Genetics

See all studies in Genetics →